<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03832569</url>
  </required_header>
  <id_info>
    <org_study_id>18-399</org_study_id>
    <nct_id>NCT03832569</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors</brief_title>
  <official_title>A Single-Arm Pilot Study of Adjuvant Pembrolizumab in Patients With MSI-H Tumors With Persistent Circulating Tumor DNA Following Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find&#xD;
      out how well it works to prevent cancer from coming back in people who have had a solid tumor&#xD;
      surgically removed, but still have tumor cells in their blood. During the study, the&#xD;
      participant will receive either the study drug or a placebo for as long as 12 months, or&#xD;
      until the cancer comes back, or the side effects of the treatment become too severe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind study of adjuvant pembrolizumab or placebo in patients with MSI-H solid tumors with persistent circulating tumor DNA (ctDNA) despite curative surgery and completion of standard perioperative and/or adjuvant therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with ctDNA clearance</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Patients who have ctDNA clearance at 12 months will be considered responders, and patients who do not have ctDNA clearance at 12 months will be considered non-responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the time from treatment start till recurrence or death whichever comes first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Identified by NGS, PCR or IHC</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Any solid tumor with MSI or MRD by IHC, PCR or NGS testing. MSKCC confirmation of&#xD;
             MSI-H/MRD status is not mandatory prior to enrollment and treatment on the study. For&#xD;
             patients with outside testing, if sufficient tissue is available NGS will be repeated&#xD;
             at MSKCC and will not impact the patient's eligibility.&#xD;
&#xD;
          -  Must have genetic testing of DNA from primary tumor for somatic genomic alterations&#xD;
             across a minimum of 50 genes.&#xD;
&#xD;
          -  Must have undergone a complete curative surgical resection (R0)&#xD;
&#xD;
          -  Must have completed standard of care (SOC) surgery, neoadjuvant or adjuvant therapy&#xD;
&#xD;
          -  To be eligible for pembrolizumab or placebo therapy, the patients must have positive&#xD;
             ctDNA (as defined in section 7.0) within 4 months after completion of appropriate&#xD;
             standard of care therapy (surgery, chemotherapy, radiation as appropriate). Note, if&#xD;
             ctDNA has a negative result, ctDNA can be re-tested up to 3 months later, within 9&#xD;
             months of completion of standard therapy.&#xD;
&#xD;
          -  Patients must sign informed consent within 4 weeks of positive ctDNA result. The 4&#xD;
             weeks is considered from the date that the ctDNA is resulted, and not the date it is&#xD;
             drawn.&#xD;
&#xD;
          -  Demonstrate adequate organ function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1,500 /mcL&#xD;
&#xD;
               -  Platelets ≥100,000 / mcL&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤1.5 X upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with&#xD;
                  total bilirubin levels &gt; 1.5 ULN. Except patients with Gilbert's disease (≤3x&#xD;
                  ULN)&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 X ULN&#xD;
&#xD;
               -  Albumin ≥3 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have not recovered from serious adverse events (as determined by treating&#xD;
             MD) related to surgery.&#xD;
&#xD;
          -  Presence of metastatic or recurrent disease.&#xD;
&#xD;
          -  Had R1 ( microscopic residual tumor) or R2 resection (macroscopic residual tumor at&#xD;
             resection margin).&#xD;
&#xD;
          -  Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          -  Patients who have received acute, low dose, systemic immunosuppressant medications&#xD;
             (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast&#xD;
             premedication) may be enrolled.&#xD;
&#xD;
          -  The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for&#xD;
             patients with orthostatic hypotension or adrenocortical insufficiency is allowed.&#xD;
&#xD;
          -  Has a known history of active TB (Bacillus tuberculosis)&#xD;
&#xD;
          -  Hypersensitivity to pembrolizumab or any of its excipients&#xD;
&#xD;
          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy&#xD;
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at&#xD;
             baseline) from adverse events due to a previously administered agent.&#xD;
&#xD;
             o Note: If subject received major surgery, they must have recovered adequately from&#xD;
             the toxicity and/or complications from the intervention prior to starting therapy.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis&#xD;
&#xD;
          -  Has known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease; systemic lupus erythematosus; Wegener syndrome&#xD;
             [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid&#xD;
             arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of&#xD;
             treatment. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Subjects with vitiligo or alopecia&#xD;
&#xD;
               -  Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement or psoriasis not requiring systemic treatment.&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
             o Note: Seasonal influenza vaccines for injection are generally inactivated flu&#xD;
             vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are&#xD;
             live attenuated vaccines, and are not allowed.&#xD;
&#xD;
          -  Is unwilling to give written informed consent, unwillingness to participate, or&#xD;
             inability to comply with the protocol for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yelena Janjigian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yelena Janjigian, MD</last_name>
    <phone>646-888-4186</phone>
    <email>janjigiy@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dmitriy Zamarin, MD, PhD</last_name>
    <phone>646-888-4882</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Janjigian, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yelena Janjigian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Janjigian, MD</last_name>
      <phone>646-888-4186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Janjigian, MD</last_name>
      <phone>646-888-4186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Janjigian, MD</last_name>
      <phone>646-888-4186</phone>
    </contact>
    <investigator>
      <last_name>Yelena Janjigian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Janjigian, MD</last_name>
      <phone>646-888-4186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Janjigian, MD</last_name>
      <phone>646-888-4186</phone>
    </contact>
    <contact_backup>
      <last_name>David Ilson, MD, PhD</last_name>
      <phone>646-888-4183</phone>
    </contact_backup>
    <investigator>
      <last_name>Yelena Janjigian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Janjigian, MD</last_name>
      <phone>646-888-4186</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2023</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>September 12, 2023</last_update_submitted>
  <last_update_submitted_qc>September 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pembrolizumab</keyword>
  <keyword>18-399</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03832569
org study id: 18-399
nct id: NCT03832569
lead sponsor: 
collaborator: 
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find
      out how well it works to prevent cancer from coming back in people who have had a solid tumor
      surgically removed, but still have tumor cells in their blood. During the study, the
      participant will receive either the study drug or a placebo for as long as 12 months, or
      until the cancer comes back, or the side effects of the treatment become too severe.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: This is a randomized, double-blind study of adjuvant pembrolizumab or placebo in patients with MSI-H solid tumors with persistent circulating tumor DNA (ctDNA) despite curative surgery and completion of standard perioperative and/or adjuvant therapy
primary purpose: Treatment
masking: None (Open Label)
measure: proportion of patients with ctDNA clearance
time frame: 12 months post randomization
description: Patients who have ctDNA clearance at 12 months will be considered responders, and patients who do not have ctDNA clearance at 12 months will be considered non-responders.
measure: disease free survival (DFS)
time frame: 5 years
description: DFS is defined as the time from treatment start till recurrence or death whichever comes first.
arm group label: Pembrolizumab
arm group type: Experimental
description: Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
intervention type: Drug
intervention name: Pembrolizumab
description: Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
arm group label: Pembrolizumab
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Yelena Janjigian, MD
role: Principal Investigator
affiliation: Memorial Sloan Kettering Cancer Center
last name: Yelena Janjigian, MD
phone: 646-888-4186
email: janjigiy@mskcc.org
last name: Dmitriy Zamarin, MD, PhD
phone: 646-888-4882
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
country: United States
url: http://www.mskcc.org/mskcc/html/44.cfm
description: Memorial Sloan Kettering Cancer Center
responsible party type: Sponsor
mesh term: Pembrolizumab
sharing ipd: Yes
ipd description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Clinical Study Report (CSR)